(LLY) Community Analysis from
Bulls REASONS TO BUY
|
90%
agree
43 votes
|
Zyprexa incredibly profitable |
|
50%
agree
2 votes
|
Strong dollar spurs quarterly profit |
Bears REASONS TO SELL
|
26%
agree
15 votes
|
Zyprexa will lose patent protection in 2011 |
|
37%
agree
37 votes
|
Zyprexa causes Diabetes |
May 24, 2013
(Stock Blog Hub,
5/3/13)
Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary...(read more)
(Stock Blog Hub,
4/21/13)
OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment...(read more)
(ValueWalk.com,
8/24/12)
According to a report in BusinessWeek , pharmaceutical major, Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), has won its case in the U.S. Court of Appeals relating to patent protection for its...(read more)
Eli Lilly and Company (LLY) Company Overview
There is no analysis for LLY yet. But you can go to Wikinvest to help create one!
What's in this LLY analysis on Wikinvest...
- Corporate Overview
- Business Segments
- Neurology (45% of 2010 Sales)
- Endrocrinology (28% of 2010 Sales)
- Oncology (16% of 2010 Sales)
- Cardiovascular (10% of 2010 Sales)
- Animal Health (6% of 2010 Sales)
- Research and Development ($4.9B in 2010)
- Trends and Forces
- The Expiration of Zyprexa Patent Exclusivity in 2011
- Pipeline Risks
- Young Product Portfolio
- Generic Drug Competition
- Tightening FDA Regulations
- Lawsuits
- Competition
- References
